Women face several blood clot risks that men simply don’t, almost all of them tied to estrogen. Pregnancy, birth control pills, hormone therapy, and certain reproductive conditions each shift the body’s clotting system in ways that can lead to dangerous clots in the veins, known as venous thromboembolism (VTE). Understanding these specific triggers helps explain why blood clots remain a serious health concern for women at nearly every stage of life.
How Estrogen Changes the Clotting System
Estrogen is the common thread behind most female-specific clot risk. When estrogen levels rise, whether naturally or from medications, the liver produces more of the proteins that make blood clot. Combined oral contraceptives increase plasma levels of clotting factors II, VII, VIII, X, and fibrinogen, effectively tipping the balance toward a “pro-thrombotic state” where blood is more likely to clot when it shouldn’t. This doesn’t mean every woman with higher estrogen will develop a clot, but it does mean the threshold for one forming is lower.
The same shift happens in postmenopausal women taking oral hormone replacement therapy. Studies in that group confirm that estrogen raises factor VII levels specifically, contributing to the same pro-clotting environment seen with birth control.
Birth Control Pills and Clot Risk
Combined hormonal contraceptives (the pill, the ring, the patch) are one of the most common reasons younger women develop blood clots. The absolute risk is still small: roughly 1 additional case of VTE per 10,000 women per year of use compared to non-users. For most women, that risk is acceptable. But it’s not evenly distributed.
Women who carry a genetic clotting mutation called Factor V Leiden face a compounding effect. In one study, women with this mutation who were prescribed estrogen had more than double the VTE rate of women without it (4.6% vs. 2.1%). The risk climbs steeply when other health conditions are layered on top: among women with Factor V Leiden and two additional medical conditions taking estrogen, 19% experienced a clot. With three additional conditions, that number hit 29%. This is why some doctors recommend clotting disorder screening before prescribing hormonal birth control, particularly for women with a family history of clots.
Progestin-only methods (the mini-pill, hormonal IUDs, the implant) don’t carry the same VTE risk because they lack the estrogen component that drives changes in clotting factors.
Pregnancy and the Postpartum Window
Pregnancy is essentially a perfect storm for clot formation. The body increases its clotting ability to prepare for the blood loss of delivery. At the same time, the growing uterus compresses the large vein in the pelvis (the inferior vena cava), slowing blood flow in the legs. Reduced mobility, especially in late pregnancy and after delivery, adds a third layer of risk. These three factors, hypercoagulability, compressed veins, and less movement, are the classic recipe for a blood clot.
The highest-risk period isn’t actually during pregnancy itself. The six weeks after delivery carry five times the clot risk of pregnancy, making the postpartum window the most dangerous stretch. This is true for both vaginal and cesarean deliveries, though surgical birth raises the risk further.
Diagnosis during pregnancy is genuinely tricky. Leg swelling, shortness of breath, a faster heart rate, and chest discomfort are all normal pregnancy symptoms, and they’re also the hallmark signs of a blood clot. Women who develop leg swelling in the first trimester have a dramatically higher likelihood (53 times higher) of that swelling being caused by an actual clot compared to women who develop it later, simply because early-pregnancy swelling is less common and more suspicious. Atypical symptoms like pain in the thigh or buttock can also signal a clot in pregnant women, which makes it easy to dismiss as a musculoskeletal complaint.
Hormone Replacement Therapy: Oral vs. Transdermal
For women going through menopause, the route of estrogen delivery matters enormously. Oral estrogen pills nearly double the risk of VTE (pooled risk ratio of 1.9). Transdermal estrogen, delivered through a skin patch or gel, carries essentially no increased clot risk at all (risk ratio of 1.0, meaning identical to not taking hormones).
The reason comes down to how the body processes estrogen. Pills pass through the liver first, where they ramp up production of clotting proteins and create resistance to one of the body’s natural anti-clotting mechanisms (activated protein C). Patches and gels bypass the liver entirely, delivering estrogen directly into the bloodstream with minimal effect on the clotting system. Even women who have already had a blood clot in the past don’t appear to face extra risk from transdermal estrogen, making it a substantially safer option for women who need menopausal hormone therapy.
PCOS as an Independent Risk Factor
Polycystic ovary syndrome (PCOS) affects roughly 1 in 10 women of reproductive age, and it carries its own clot risk that goes beyond the obvious contributing factors. A meta-analysis found that women with PCOS have 1.5 to 2 times the risk of VTE compared to women without it. The important finding is that this elevated risk persists even after accounting for obesity and birth control pill use, both of which are more common in women with PCOS. Something about the condition itself, likely related to chronic inflammation and metabolic disruption, independently raises clot risk.
An Anatomical Factor: May-Thurner Syndrome
Some women have a structural issue in their pelvis that predisposes them to left-leg blood clots. In May-Thurner syndrome, the right iliac artery crosses over and compresses the left iliac vein, narrowing the channel that returns blood from the left leg to the heart. The effect is similar to stepping on a garden hose: blood flow slows, and the stagnant blood is more likely to clot. This condition is slightly more common in women and can also contribute to chronic pelvic pain through a related condition called pelvic congestion syndrome. Many people with May-Thurner syndrome don’t know they have it until a clot develops.
Travel and Compounding Risk Factors
Long-distance travel (generally four hours or more of sitting) raises clot risk for everyone, but women face a uniquely layered version of this risk. The CDC lists estrogen-containing contraceptives, hormone replacement therapy, pregnancy, and the postpartum period (up to three months after childbirth) as specific risk factors that combine with prolonged sitting to increase clot likelihood. A healthy 25-year-old woman on birth control taking a long flight has a meaningfully different risk profile than the same woman not on hormonal contraception.
The more risk factors that stack up, the greater the danger. A woman who is pregnant, over 40, with varicose veins and limited mobility faces a compounding effect where each additional factor multiplies rather than simply adds to the overall risk. Staying hydrated, moving your legs regularly, and wearing compression stockings during long travel are simple measures that help keep blood flowing.
When Genetics and Hormones Collide
Factor V Leiden is the most common inherited clotting disorder, carried by about 5% of people of European descent. On its own, it modestly increases clot risk. Combined with estrogen, the effect is synergistic, meaning the two together create far more risk than either one alone. This interaction is especially pronounced in women with multiple health conditions. The research shows a clear dose-response pattern: as medical conditions accumulate alongside Factor V Leiden and estrogen use, VTE prevalence escalates from 1% (no additional conditions) to 29% (three additional conditions).
Other inherited clotting disorders, including antithrombin deficiency and having two copies of the Factor V Leiden mutation, carry even higher baseline risk. Current hematology guidelines recommend preventive blood thinners during pregnancy and after delivery for women with these high-risk genetic profiles, particularly when there’s also a family history of clots.
Recognizing Clot Symptoms
A deep vein clot (DVT) typically causes pain and swelling in one leg, often the calf or thigh. The leg may feel warm to the touch and look reddened or discolored. If a clot breaks free and travels to the lungs (pulmonary embolism), symptoms shift to shortness of breath (the most common sign, present in about 35% of cases), chest pain that worsens with breathing, a rapid heart rate, and sometimes leg weakness. These symptoms deserve urgent medical evaluation, especially in women with any of the risk factors described above. During pregnancy, any unusual or one-sided leg swelling, unexplained breathlessness, or chest pain warrants a call to your provider rather than waiting for your next appointment.